Table 6. . Longitudinal model/mean change in quality of life or symptom scores.
| Study | Treatment | Global QoL | Fatigue | Pain | Cough | Dyspnea | Ref. |
|---|---|---|---|---|---|---|---|
| LUME-Lung 1 Adenocarcinoma patients |
Docetaxel + placebo Docetaxel + nintedanib |
Trend favoring nintedanib | – | Trend favoring nintedanib | Trend favoring nintedanib | NS | [4,17] |
| CheckMate 017 | Nivolumab Docetaxel |
Trend favoring nivolumab on LCSS and ASBI | – | – | – | – | [13,16] |
| TAX-317 | Docetaxel (overall) Best supportive care |
Trend favoring docetaxel only | NS | Favored docetaxel | NS | NS | [23] |
ASBI: Average symptom burden index; LCSS, Lung Cancer Symptom Scale; NS: Not significant; QoL: Quality of life.